Product Name
OTEZLA TABLET STARTER PACK
OTEZLA TABLET 30 MG
Active Ingredient
Apremilast
Product Registrant
AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD
Date of Approval
02/12/2022
Indications:
Otezla is indicated for
· The treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.
IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION 50 MG/ML
Durvalumab
ASTRAZENECA SINGAPORE PTE LTD
12/12/2022
IMFINZI in combination with cisplatin and gemcitabine, is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer (BTC).
DENGVAXIA POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION
CYD dengue virus serotype 1
CYD dengue virus serotype 2
CYD dengue virus serotype 3
CYD dengue virus serotype 4
SANOFI-AVENTIS SINGAPORE PTE. LTD.
13 December 2022
Dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 12 through 45 years of age with test-confirmed previous dengue infection.
New Drug Indication Approvals